Investment Analysts’ Recent Ratings Updates for Biohaven (BHVN)

A number of research firms have changed their ratings and price targets for Biohaven (NYSE: BHVN):

  • 11/19/2026 – Biohaven had its price target raised by JPMorgan Chase & Co. from $14.00 to $35.00. They now have an “overweight” rating on the stock.
  • 11/7/2026 – Biohaven was downgraded by Wall Street Zen from “hold” to “sell”.
  • 11/3/2026 – Biohaven had its price target raised by Morgan Stanley from $19.00 to $21.00. They now have an “overweight” rating on the stock.
  • 11/2/2026 – Biohaven was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 10/30/2026 – Biohaven had its price target raised by Canaccord Genuity Group from $21.00 to $32.00. They now have a “buy” rating on the stock.
  • 10/24/2026 – Biohaven was upgraded by Wall Street Zen from “sell” to “hold”.
  • 10/23/2026 – Biohaven had its price target raised by Royal Bank Of Canada from $19.00 to $22.00. They now have a “sector perform” rating on the stock.
  • 10/22/2026 – Biohaven was given a new $48.00 price target by Robert W. Baird.
  • 10/8/2026 – Biohaven had its “strong-buy” rating reaffirmed by Raymond James Financial.

Biohaven Trading Up 5.6%

Shares of NYSE BHVN opened at $13.62 on Friday. The company has a debt-to-equity ratio of 21.23, a current ratio of 3.05 and a quick ratio of 3.05. Biohaven Ltd. has a fifty-two week low of $8.03 and a fifty-two week high of $18.24. The firm has a market capitalization of $2.06 billion, a P/E ratio of -3.53 and a beta of 1.36. The company’s 50 day simple moving average is $13.42 and its 200 day simple moving average is $12.38.

Biohaven Ltd. is a clinical-stage biopharmaceutical company developing treatments for neurological, immunological and other serious diseases. Its research programs include potential therapies for epilepsy and autoimmune conditions, as well as medicines designed to target disease-related proteins and antibodies. The company’s pipeline includes investigational candidates that act on ion channels and immune pathways. These programs are in development and are not approved medicines; Biohaven does not have a marketed product portfolio.

Featured Stories

Receive News & Ratings for Biohaven Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Ltd and related companies with MarketBeat.com's FREE daily email newsletter.